ThromboGenics and VIB launch New Oncology Company - Seite 2

Johan Cardoen, Managing Director of VIB said," We are excited that we can jointly translate the potential of VIB research by Prof. Peter Carmeliet into a reality for patients. We believe that TB-403 has the potential to greatly improve the treatment of medulloblastoma and a number of other pediatric tumours, an area of great medical need. This collaboration illustrates the value of excellence-driven basic research at VIB and ThromboGenics, and the pro-active approach to "make the difference for patients". We are confident that together with ThromboGenics, we can develop Oncurious into a leading oncology company."

BioInvent International AB will act as a co-development partner for this oncology project. 

ThromboGenics has retained the exclusive license for use of TB-403 in ophthalmic indications.

Ends

For further information please contact:

ThromboGenics Wouter Piepers, Global Head of Corporate Communications & Investor Relations [phone] / [phone] [e-mail]

VIB Johan Cardoen, Managing Director VIB [phone] / [phone] [e-mail]

 

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA^® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. 

ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA^® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

About VIB

VIB is an excellence-driven life sciences research institute in Flanders, Belgium. VIB aims to push the limits of our understanding of molecular mechanisms of life and disease and provides a stimulating environment to its scientists. VIB unites the expertise of 1400 scientists originating from over 60 countries in a single institute. Since its inception VIB is also an entrepreneurial biotechnology catalyst focusing on translating basic scientific breakthroughs into pharmaceutical, agricultural and industrial applications. In this context, VIB pro-actively translates biological insights into proof-of-concept stage assets which can be the basis for active partnering with industrial players or the launch of new Venture Capital-backed biotechnology companies. VIB also actively engages in the public debate on biotechnology by developing and disseminating a wide range of science-based information about all aspects of biotechnology. VIB has a close partnership with four Flemish universities - Ghent University, KU Leuven, University of Antwerp, and Vrije Universiteit Brussel. More info www.vib.be.